Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

CalciMedica, Inc.

NASDAQ: CALC · Life Sciences · 5 alerts · CIK 1534133

Share price
$1.19Close, Nov 16
Market cap
$8.21M
Shares outstanding
6.9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CalciMedica, Inc. filings on SEC EDGAR ↗

4:16 PM ET 10-Q
Financial Results

CalciMedica Q3 2026 Results: Net Loss of $1.7M, Loss Narrows

CalciMedica reported a net loss of $4.35 million for the nine months ended September 30, 2026, a significant improvement from the $18.80 million loss in the prior year period, primarily driven by a $10.5 million gain from the change in fair value of financial instruments. Total operating expenses decreased to $14.37 million from $18.74 million, while the company strengthened its cash position through private placements and warrant exercises.

Key figure
Net loss $1.7M
7:15 AM ET 8-K
Financial Results

CalciMedica Financial Results

CalciMedica reported third quarter 2026 financial results, ending the period with $13.8 million in cash which is expected to fund operations into the second half of 2027. The company highlighted clinical progress in its pulmonary hypertension and acute pancreatitis programs, with Phase 1b data for Auxora expected in mid-2027. Additionally, the company completed a 1-for-5 reverse stock split in August 2026 to regain Nasdaq compliance.

Term
3 years

“We continue to advance our pulmonary hypertension strategy, with data from the Auxora Phase 1b proof-of-concept trial in PH and the CM5480 IND submission both anticipated in mid-2027. Preclinical models suggest CRAC channel inhibitors may provide a differentiated approach in pulmonary hypertension by targeting multiple disease drivers, including right ventricular dysfunction, which is the principal cause of mortality and not directly targeted by existing therapies.”

Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica
4:47 PM ET 8-K
Leadership Change

CalciMedica Leadership Change

Stephen Bardin, the Chief Financial Officer, principal accounting officer, and principal financial officer of CalciMedica, Inc., has resigned to pursue another professional opportunity. The resignation is effective immediately following the filing of the company's Quarterly Report on Form 10-Q for the period ended September 30, 2026, and was not due to any disagreement with the company.

4:07 PM ET 8-K
Other 8-K Filing

CalciMedica Other 8-K Filing

CalciMedica filed a prospectus supplement to establish an at-the-market (ATM) offering program for the sale of up to $25 million of its common stock. The sales may occur from time to time through H.C. Wainwright & Co. under an existing offering agreement. As of this filing, no shares have been sold and no proceeds have been received.

Counterparty
H.C. Wainwright & Co.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.